GlassScriptPhysician profile
Michelle R Dudzinski
NPI 1043266091
$832.38
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $219.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $171.44 | 2019-2020 | |
| Clovis Oncology, INC. | $151.60 | 2019-2020 | |
| Glaxosmithkline, LLC. | $139.97 | 2020 | |
| Merck Sharp & Dohme LLC | $72.59 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $69.84 | 2019-2020 | |
| Daiichi Sankyo INC. | $54.25 | 2019 | |
| Janssen Biotech, INC. | $49.42 | 2019 | |
| Smith+Nephew, INC. | $30.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.49 | 2019 | |
| Lilly USA, LLC | $15.85 | 2019 | |
| Tesaro, INC. | $12.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.19 | 2019 | |
| Genzyme Corporation | $11.85 | 2019 | |
| Angiodynamics, INC. | $11.83 | 2019 | |
| Verastem, INC. | $11.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Dudzinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.